相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer
Jie Cheng et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
S. Valpione et al.
EUROPEAN JOURNAL OF CANCER (2018)
Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR
Vera Kloten et al.
ONCOTARGET (2017)
Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols
Lise B. Ahlborn et al.
CLINICAL LABORATORY (2017)
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials
Emmanuelle Kempf et al.
PLOS ONE (2016)
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
J. Andrew Livingston et al.
ONCOTARGET (2016)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms AMeta-analysis
Maria Schwaederle et al.
JAMA ONCOLOGY (2016)
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
Steffen Dietz et al.
PLOS ONE (2016)
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification
Alison S. Devonshire et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2014)
Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies
Ida Elisabeth Viller Tuxen et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
A. Ploquin et al.
BRITISH JOURNAL OF CANCER (2012)
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
Ignacio Garrido-Laguna et al.
CANCER (2012)
Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Jennifer Wheler et al.
CLINICAL CANCER RESEARCH (2012)
Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models
Anne Ploquin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
David Olmos et al.
CLINICAL CANCER RESEARCH (2011)
Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau et al.
BRITISH JOURNAL OF CANCER (2008)
Circulating nucleic acids (CNAs) and cancer - A survey
M. Fleischhacker et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2007)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Circulating DNA in plasma and serum: Biology, preanalytical issues and diagnostic applications
YYN Lui et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
T Bachelot et al.
ANNALS OF ONCOLOGY (2000)
分享论文
